Literature DB >> 23058054

Combined effect of sildenafil and guanethidine, propranolol or verapamil on erectile function in rats.

Amira M Senbel1, Ahmed M Hashad, Fouad M Sharabi, Tahia T Daabees.   

Abstract

OBJECTIVES: This study aims to further elucidate the role of adrenergic transmission in erection and to highlight whether adrenergic transmission in the penis modulates sildenafil's action.
METHODS: Measurement of intracavernosal pressure in the anesthetized rat model. KEY
FINDINGS: Guanethidine (3 and 6 mg/kg) potentiated intracavernosal pressure/mean arterial pressure (ICP/MAP) rises in response to cavernous nerve stimulation by 4.375 ± 0.425 and 18.375 ± 1.085% respectively. Propranolol did the opposite. In presence of guanethidine, sildenafil (0.01, 0.1 and 1 mg/kg) potentiated ICP/MAP responses by 81.571 ± 4.918%, 147.83 ± 10.864% and 279.285 ± 23.053% at 1 Hz compared to 22.277 ± 2.139%, 123.571 ± 8.443% and 186.25 ± 13.542% respectively in the absence of guanethidine. Propranolol inhibited the effect sildenafil at all frequencies of stimulation. Verapamil exhibited a pro-erectile action and potentiated the effect of sildenafil (0.01, 0.1 and 1 mg/kg) on erectile responses corresponding to 85.25 ± 6.716%, 146 ± 11.288% and 221.571 ± 19.032% respectively compared to 26.011 ± 1.911%, 87.142 ± 8.73% and 182.2 ± 16.921% in its absence.
CONCLUSIONS: This study provides functional evidence that inhibition of sympathetic tone peripherally results in enhancement of erectile function. β-adrenergic receptors seem to play an important role in erection. The combination of sildenafil and guanethidine or verapamil could have a potential advantage on erectile function but propranolol may mask the effect of sildenafil on erectile function.
© 2012 The Authors. JPP © 2012 Royal Pharmaceutical Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23058054     DOI: 10.1111/j.2042-7158.2012.01548.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  1 in total

1.  Effectiveness and Safety of Intracavernosal IncobotulinumtoxinA (Xeomin®) 100 U as an Add-on Therapy to Standard Pharmacological Treatment for Difficult-to-Treat Erectile Dysfunction: A Case Series.

Authors:  Francois Giuliano; Pierre Denys; Charles Joussain
Journal:  Toxins (Basel)       Date:  2022-04-16       Impact factor: 5.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.